Yoann Barthe

Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) – NCT01514890

Christophe Hézode, Hélène Fontaine, Céline Dorival et al. · Journal of Hepatology · 2013 · 431 citations

Pharmacy, Internal Medicine, Pharmacotherapy +12

Effectiveness of Telaprevir or Boceprevir in Treatment-Experienced Patients With HCV Genotype 1 Infection and Cirrhosis

Christophe Hézode, Hélène Fontaine, Céline Dorival et al. · Gastroenterology · 2014 · 260 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +14

Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trial

Marc Bourlière, Pascaline Rabiéga, Nathalie Ganne‐Carrié et al. · ˜The œLancet. Gastroenterology & hepatology · 2017 · 119 citations

Pharmacy, Immunology, Pharmacotherapy +17

Antiviral therapy is associated with a better survival in patients with hepatitis C virus and B‐cell non‐Hodgkin lymphomas, ANRS HC‐13 lympho‐C study

Jean‐Marie Michot, Danielle Canioni, Henda Driss et al. · American Journal of Hematology · 2014 · 116 citations

Medicine, Hematology, Oncology +16

8 SAFETY OF TELAPREVIR OR BOCEPREVIR IN COMBINATION WITH PEGINTERFERON ALFA/RIBAVIRIN, IN CIRRHOTIC NON RESPONDERS. FIRST RESULTS OF THE FRENCH EARLY ACCESS PROGRAM (ANRS CO20-CUPIC)

C. Hézode, Céline Dorival, Fabien Zoulim et al. · Journal of Hepatology · 2012 · 88 citations

Pharmacy, Pharmacotherapy, Hepatitis Pharmacotherapy +10